%0 Journal Article
%A Vallejo Casas, Juan Antonio
%A Sambo, Marcel
%A Lopez Lopez, Carlos
%A Duran-Poveda, Manuel
%A Rodriguez-Villanueva Garcia, Julio
%A Santos, Rita Joana
%A Llanos, Marta
%A Navarro-Gonzalez, Elena
%A Aller, Javier
%A Pubul, Virginia
%A Guadalix, Sonsoles
%A Crespo, Guillermo
%A Gonzalez, Cintia
%A Zafon, Carles
%A Navarro, Miguel
%A Santamaria-Sandi, Javier
%A Segura, Angel
%A Gajate, Pablo
%A Gomez-Balaguer, Marcelino
%A Valdivia, Javier
%A Puig-Domingo, Manel
%A Galofre, Juan Carlos
%A Castelo, Beatriz
%A Villanueva, Maria Jose
%A Argüelles, Iñaki
%A Orcajo-Rincon, Lorenzo
%T Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study.
%D 2022
%@ 2235-0640
%U http://hdl.handle.net/10668/20449
%X Up to 30% of differentiated thyroid cancer (DTC) will develop advanced-stage disease (aDTC) with reduced overall survival (OS). The aim of this study is to characterize initial diagnosis of aDTC, its therapeutic management, and prognosis in Spain and Portugal. A multicentre, longitudinal, retrospective study of adult patients diagnosed with aDTC in the Iberian Peninsula was conducted between January 2007 and December 2012. Analyses of baseline characteristics and results of initial treatments, relapse- or progression-free survival ((RP)FS) from first DTC diagnosis, OS, and prognostic factors impacting the evolution of advanced disease were evaluated. Two hundred and thirteen patients (median age: 63 years; 57% female) were eligible from 23 hospitals. Advanced disease presented at first diagnosis (de novo aDTC) included 54% of patients, while 46% had relapsed from early disease (recurrent/progressive eDTC). At initial stage, most patients received surgery (98%) and/or radioiodine (RAI) (89%), with no differences seen between median OS (95% CI) (10.4 (7.3-15.3) years) and median disease-specific-survival (95% CI) (11.1 (8.7-16.2) years; log-rank test P = 0.4737). Age at diagnosis being  Identification of early treatment-dependent prognostic factors for an unfavourable course of advanced disease is possible. An intensified therapeutic attitude may reverse this trend and should be considered in poor-performing patients. Prospective studies are required to confirm these findings.
%K Advanced differentiated thyroid cancer
%K Epidemiological study
%K Radioiodine-refractory differentiated thyroid cancer
%K Relapsing differentiated thyroid cancer
%K Relapsing prognostic factors
%K Survival prognostic factors
%~